Prospera Financial Services Inc Catalyst Pharmaceuticals, Inc. Transaction History

Prospera Financial Services Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$14.68 - $16.92 $93,423 - $107,678	-6,364 Reduced 34.41%	12,128 $187,000
Q1 2024 Aug 13, 2024	BUY	$13.18 - $17.11 $51,995 - $67,498	3,945 Added 32.53%	16,073 $256,000
Q4 2023 Feb 14, 2024	BUY	$11.78 - $17.29 $15,914 - $23,358	1,351 Added 7.88%	18,492 $310,000
Q2 2023 Aug 08, 2023	SELL	$11.5 - $18.08 $3,576 - $5,622	-311 Reduced 1.78%	17,141 $230,000
Q1 2023 May 12, 2023	BUY	$14.34 - $21.05 $9,048 - $13,282	631 Added 3.75%	17,452 $289,000
Q4 2022 Feb 08, 2023	SELL	$12.25 - $19.5 $119,939 - $190,924	-9,791 Reduced 36.79%	16,821 $312,000
Q3 2022 Oct 27, 2022	SELL	$7.06 - $15.52 $13,639 - $29,984	-1,932 Reduced 6.77%	26,612 $341,000
Q2 2022 Aug 08, 2022	SELL	$6.23 - $8.57 $14,079 - $19,368	-2,260 Reduced 7.34%	28,544 $200,000
Q1 2022 May 04, 2022	SELL	$5.31 - $8.31 $24,351 - $38,109	-4,586 Reduced 12.96%	30,804 $255,000
Q4 2021 Feb 10, 2022	BUY	$5.21 - $7.45 $184,381 - $263,655	35,390 New	35,390 $240,000

326

94.6M

19.1K

51.1K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.12B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Prospera Financial Services Inc, based on Form 13F filings with the SEC.

Stay updated on Prospera Financial Services Inc with notifications on news.